pelacarsen

News

Novartis hit as Lp(a) drug fails cardio outcomes trial

Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

Amgen eyes swift move to ph3 for cardiovascular drug olpasir...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

Novartis hit as Lp(a) drug fails cardio outcomes trial

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Amgen eyes swift move to ph3 for cardiovascular drug olpasir...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks